TriangleNCT02939183 · OUTCOME
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Oprozomib
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- hour*ng/mL
- Interval / dispersion
- Standard Deviation
- Time frame
- Cycle 1 days 8 and 22: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose. GR only: cycle 1 day 8: 8 hours post-dose
What was measured
The mean AUClast of oprozomib is presented following dosing on cycle 1 day 8 and cycle 1 day 22 for the IR and GR oprozomib formulations.
Analysis population: Participants in the PK analysis set with data available at each time point. The PK analysis set included participants for whom at least 1 PK parameter could be adequately estimated, excluding roll-over participants.
Groups in this outcome
Oprozomib IR 150 mg/Day + Dexamethsone
In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.
Oprozomib GR 150 mg/Day + Dexamethasone
In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.
Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone
In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone
In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone
In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone
In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone
In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone
In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
| Group | Source count |
|---|---|
| Oprozomib IR 150 mg/Day + Dexamethsone | 3 |
| Oprozomib GR 150 mg/Day + Dexamethasone | 6 |
| Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone | 3 |
| Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone | 3 |
| Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone | 7 |
| Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone | 5 |
| Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone | 10 |
| Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone | 7 |
Reported measurements
Cycle 1 Day 8
| Group | Source count |
|---|---|
| Oprozomib IR 150 mg/Day + Dexamethsone | 3 |
| Oprozomib GR 150 mg/Day + Dexamethasone | 4 |
| Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone | 3 |
| Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone | 3 |
| Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone | 7 |
| Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone | 5 |
| Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone | 10 |
| Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone | 7 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Oprozomib IR 150 mg/Day + Dexamethsone | 656 | 77.6 | Not reported | Not reported | Not reported |
| Oprozomib GR 150 mg/Day + Dexamethasone | 357 | 252 | Not reported | Not reported | Not reported |
| Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone | 869 | 449 | Not reported | Not reported | Not reported |
| Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone | 655 | 73.5 | Not reported | Not reported | Not reported |
| Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone | 1210 | 658 | Not reported | Not reported | Not reported |
| Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone | 1880 | 2190 | Not reported | Not reported | Not reported |
| Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone | 1730 | 1160 | Not reported | Not reported | Not reported |
| Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone | 1710 | 1560 | Not reported | Not reported | Not reported |
Cycle 1 Day 22
| Group | Source count |
|---|---|
| Oprozomib IR 150 mg/Day + Dexamethsone | 3 |
| Oprozomib GR 150 mg/Day + Dexamethasone | 6 |
| Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone | 1 |
| Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone | 3 |
| Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone | 4 |
| Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone | 4 |
| Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone | 10 |
| Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone | 4 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Oprozomib IR 150 mg/Day + Dexamethsone | 1020 | 281 | Not reported | Not reported | Not reported |
| Oprozomib GR 150 mg/Day + Dexamethasone | 1380 | 1090 | Not reported | Not reported | Not reported |
| Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone | 681 | NA | Not reported | Not reported | The SD could not be determined due to too few participants with available data at this time point. |
| Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone | 839 | 544 | Not reported | Not reported | Not reported |
| Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone | 1420 | 659 | Not reported | Not reported | Not reported |
| Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone | 888 | 1200 | Not reported | Not reported | Not reported |
| Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone | 2050 | 722 | Not reported | Not reported | Not reported |
| Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone | 2030 | 1070 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 77.6
- value
- 656
- group Id
- OG001
- spread
- 252
- value
- 357
- group Id
- OG002
- spread
- 449
- value
- 869
- group Id
- OG003
- spread
- 73.5
- value
- 655
- group Id
- OG004
- spread
- 658
- value
- 1210
- group Id
- OG005
- spread
- 2190
- value
- 1880
- group Id
- OG006
- spread
- 1160
- value
- 1730
- group Id
- OG007
- spread
- 1560
- value
- 1710
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 7
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 10
- group Id
- OG007
- value
- 7
- units
- Participants
- title
- Cycle 1 Day 8
- categories
- measurements
- group Id
- OG000
- spread
- 281
- value
- 1020
- group Id
- OG001
- spread
- 1090
- value
- 1380
- comment
- The SD could not be determined due to too few participants with available data at this time point.
- group Id
- OG002
- spread
- NA
- value
- 681
- group Id
- OG003
- spread
- 544
- value
- 839
- group Id
- OG004
- spread
- 659
- value
- 1420
- group Id
- OG005
- spread
- 1200
- value
- 888
- group Id
- OG006
- spread
- 722
- value
- 2050
- group Id
- OG007
- spread
- 1070
- value
- 2030
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 6
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 4
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 10
- group Id
- OG007
- value
- 4
- units
- Participants
- title
- Cycle 1 Day 22
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 6
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 7
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 10
- group Id
- OG007
- value
- 7
- units
- Participants
- description
- The mean AUClast of oprozomib is presented following dosing on cycle 1 day 8 and cycle 1 day 22 for the IR and GR oprozomib formulations.
- dispersion Type
- Standard Deviation
- groups
- description
- In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.
- id
- OG000
- title
- Oprozomib IR 150 mg/Day + Dexamethsone
- description
- In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.
- id
- OG001
- title
- Oprozomib GR 150 mg/Day + Dexamethasone
- description
- In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
- id
- OG002
- title
- Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone
- description
- In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
- id
- OG003
- title
- Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone
- description
- In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
- id
- OG004
- title
- Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone
- description
- In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
- id
- OG005
- title
- Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone
- description
- In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
- id
- OG006
- title
- Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone
- description
- In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
- id
- OG007
- title
- Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone
- param Type
- MEAN
- population Description
- Participants in the PK analysis set with data available at each time point. The PK analysis set included participants for whom at least 1 PK parameter could be adequately estimated, excluding roll-over participants.
- reporting Status
- POSTED
- time Frame
- Cycle 1 days 8 and 22: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose. GR only: cycle 1 day 8: 8 hours post-dose
- title
- Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Oprozomib
- type
- SECONDARY
- unit Of Measure
- hour*ng/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice